Immunotherapy in Triple-Negative Breast Cancer.

Oncol Ther · 2025 · PMC12378256 · PMID 40418298

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

There was a favorable trend in survival in the experimental arm; however, the EFS outcomes were still immature [HR 0.76; 95% confidence interval (CI) 0.40–1.44] after a follow-up of 20.6 months [ 14 ].

also in 932 other papers

did not reach statistical significanceno p-value reported

The pCR rate after treatment with atezolizumab (48.6%) did not reach statistical significance compared with that after treatment without atezolizumab [44.4%, odds ratio (OR) 1.18]; follow-up for EFS is ongoing [ 13 ].

also in 60,398 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.